Amgen Stock Surges on Strong Q2 Performance Amid Growing Risks

Amgen's stock price jumped around 5% in a single session after its Q2 results exceeded expectations, reaching about $408. The company reported a revenue of over $10 billion and basic earnings per share above $4. This milestone marks a significant step towards proving the bullish view that Amgen's broad volume growth and late-stage pipeline can offset losses of exclusivity.

The growth narrative relies on newer drugs and biosimilars carrying the load, which management attributes to six key drivers growing around 26% year-over-year. However, this progress is tempered by erosion in Prolia/XGEVA and the loss of AMG 513 in obesity.

Amgen's risk stack also includes regulatory, product concentration, and integration risks that could cap long-term returns. The company faces patent cliffs, margin pressure from competition, and ongoing issues with Tavneos, an asset under scrutiny for safety and data integrity concerns.